Verrica Pharmaceuticals Dirección
Dirección controles de criterios 2/4
El CEO de Verrica Pharmaceuticals' es Ted White , nombrado en Dec 2017, tiene una permanencia de 6.33 años. compensación anual total es $1.94M, compuesta por 29.5% salario y 70.5% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.22% de las acciones de la empresa, por valor de $645.68K. La antigüedad media del equipo directivo y de la junta directiva es de 4.5 años y 5.9 años, respectivamente.
Información clave
Ted White
Chief Executive Officer (CEO)
US$3.5m
Compensación total
Porcentaje del salario del CEO | 17.1% |
Permanencia del CEO | 6.5yrs |
Participación del CEO | 0.4% |
Permanencia media de la dirección | 4.7yrs |
Promedio de permanencia en la Junta Directiva | 6.1yrs |
Actualizaciones recientes de la dirección
Recent updates
Is Verrica Pharmaceuticals (NASDAQ:VRCA) Using Debt In A Risky Way?
Jan 11Here's Why We're Not At All Concerned With Verrica Pharmaceuticals' (NASDAQ:VRCA) Cash Burn Situation
Jun 28We're Hopeful That Verrica Pharmaceuticals (NASDAQ:VRCA) Will Use Its Cash Wisely
Feb 05Vectoring Back In On Verrica Pharmaceuticals
Aug 31Verrica Pharmaceuticals reports insider buying
Jul 06Verrica Pharmaceuticals stock slides on proposed share offering
Jun 29Verrica Pharmaceuticals Should Receive Second CRL Today
May 24Auditors Have Doubts About Verrica Pharmaceuticals (NASDAQ:VRCA)
Mar 07Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Mar 06Time To Worry? Analysts Just Downgraded Their Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Outlook
Dec 17FDA extends review period for Verrica Pharmaceuticals' VP-102 NDA
May 28Verrica Pharmaceuticals EPS beats by $0.32
May 07Verrica Pharma refiles US application for lead candidate in infectious skin disease
Dec 23Verrica Pharma receives final FDA minutes regarding NDA resubmission for VP-102 in molluscum
Nov 17Verrica Pharma' VP-102 successful in mid-stage study for genital warts
Nov 10Verrica Pharmaceuticals EPS misses by $0.02
Nov 09Análisis de compensación del CEO
Fecha | Compensación total | Salario | Ingresos de la empresa |
---|---|---|---|
Mar 31 2024 | n/a | n/a | -US$81m |
Dec 31 2023 | US$4m | US$601k | -US$67m |
Sep 30 2023 | n/a | n/a | -US$48m |
Jun 30 2023 | n/a | n/a | -US$23m |
Mar 31 2023 | n/a | n/a | -US$23m |
Dec 31 2022 | US$2m | US$572k | -US$24m |
Sep 30 2022 | n/a | n/a | -US$28m |
Jun 30 2022 | n/a | n/a | -US$41m |
Mar 31 2022 | n/a | n/a | -US$43m |
Dec 31 2021 | US$2m | US$550k | -US$35m |
Sep 30 2021 | n/a | n/a | -US$39m |
Jun 30 2021 | n/a | n/a | -US$36m |
Mar 31 2021 | n/a | n/a | -US$34m |
Dec 31 2020 | US$2m | US$485k | -US$43m |
Sep 30 2020 | n/a | n/a | -US$37m |
Jun 30 2020 | n/a | n/a | -US$33m |
Mar 31 2020 | n/a | n/a | -US$31m |
Dec 31 2019 | US$1m | US$433k | -US$28m |
Sep 30 2019 | n/a | n/a | -US$28m |
Jun 30 2019 | n/a | n/a | -US$28m |
Mar 31 2019 | n/a | n/a | -US$26m |
Dec 31 2018 | US$5m | US$400k | -US$21m |
Sep 30 2018 | n/a | n/a | -US$20m |
Jun 30 2018 | n/a | n/a | -US$15m |
Mar 31 2018 | n/a | n/a | -US$11m |
Dec 31 2017 | US$24k | US$24k | -US$10m |
Compensación vs. Mercado: La compensación total de Ted($USD3.50M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD1.63M).
Compensación vs. Ingresos: La compensación de Ted ha aumentado mientras la empresa no es rentable.
CEO
Ted White (59 yo)
6.5yrs
Permanencia
US$3,504,647
Compensación
Mr. Ted White has been the President and Chief Executive Officer at Verrica Pharmaceuticals Inc. since December 2017 and has been its Director since May 2018. Mr. White served as the President and General...
Equipo directivo
Nombre | Posición | Permanencia | Compensación | Propiedad |
---|---|---|---|---|
President | 6.5yrs | US$3.50m | 0.40% $ 1.5m | |
Chief Legal Officer | 5.8yrs | US$2.56m | 0.29% $ 1.1m | |
Chief Commercial Officer | 6.3yrs | US$2.10m | 0.22% $ 790.9k | |
Chief Financial Officer | 2.9yrs | sin datos | 0.081% $ 294.6k | |
Chief Medical Officer | 3.9yrs | US$989.18k | 0.10% $ 363.8k | |
Executive Vice President of Technical Operations | 4.7yrs | sin datos | sin datos | |
Head of Drug Development | 3.8yrs | sin datos | sin datos |
4.7yrs
Permanencia media
59.5yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de VRCA se considera experimentado (4.5 años antigüedad media).
Miembros de la Junta
Nombre | Posición | Permanencia | Compensación | Propiedad |
---|---|---|---|---|
President | 6.1yrs | US$3.50m | 0.40% $ 1.5m | |
Independent Director | 6.1yrs | US$119.19k | 0% $ 0 | |
Member of Scientific Advisory Board | no data | sin datos | sin datos | |
Independent Director | 3.9yrs | US$119.19k | 0% $ 0 | |
Director | 8.5yrs | sin datos | 1.09% $ 4.0m | |
Chairman of the Board | 8.5yrs | sin datos | 36.15% $ 131.2m | |
Independent Director | 5yrs | US$119.19k | 0.024% $ 85.6k | |
Member of Scientific Advisory Board | no data | sin datos | sin datos | |
Member of Scientific Advisory Board | no data | sin datos | sin datos | |
Member of Scientific Advisory Board | no data | sin datos | sin datos | |
Member of Scientific Advisory Board | no data | sin datos | sin datos | |
Member of Scientific Advisory Board | no data | sin datos | sin datos |
6.1yrs
Permanencia media
61yo
Promedio de edad
Junta con experiencia: La junta directiva de VRCA se considera experimentada (5.9 años de antigüedad promedio).